Nothing said here yet.
to join the conversation.
ResMed (RMD) just posted quarterly results that topped analyst expectations on both earnings and revenue, while reaffirming its full year outlook and highlighting firm demand for sleep devices, masks, and digital health tools.
Moby summary of ResMed Inc.'s Q1 2027 earnings call
Medical device company ResMed (NYSE:RMD) announced better-than-expected revenue in calendar Q3 2026 (fiscal Q1 2027), with revenue rising 5.9% year on year to $1.41 billion. Its non-GAAP profit of $2.91 per share was 8.9% above analysts’ consensus estimates.
ResMed (NYSE:RMD) reported first-quarter fiscal 2027 revenue of $1.4 billion, up 6% from a year earlier on a reported basis and 7% on a core constant-currency basis, as growth in sleep devices, masks and residential care software offset declines in…
SAN DIEGO (AP) — SAN DIEGO (AP) — ResMed Inc. (RMD) on Thursday reported fiscal first-quarter net income of $418.
Q1 revenue increased by 6% to $1.4 billion; up 7% on a core constant currency basisQ1 GAAP diluted earnings per share up 23% to $2.92; non-GAAP diluted EPS up 14% to $2.91Returned more than $1.0 billion to shareholders through share repurchases and dividends…
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for ResMed (RMD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2026.
Medical device company ResMed (NYSE:RMD) will be reporting results this Thursday after market hours. Here’s what you need to know.
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
RMD heads into Q1 fiscal 2027 earnings with sleep device demand and new product launches supporting growth, while MatrixCare's divestiture weighs on revenues.
ResMed has launched the AirTouch F40 CPAP mask in the U.S., a fabric-cushioned, minimalist design that connects into its myAir and AirView platforms and is intended to support comfort, adherence and easier fitting for obstructive sleep apnea patients.
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.